newsfilter
← Latest News
GlobeNewswire·

Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026

COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasia Society being